Blair William & Co. IL Has $28.96 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Blair William & Co. IL trimmed its stake in Edwards Lifesciences by 4.6%, selling 17,780 shares and finishing the quarter with 372,353 shares valued at roughly $28.96 million.
• Edwards reported quarterly EPS of $0.58 (missing consensus by $0.04) while revenue of $1.57 billion beat estimates and rose 13.3% year-over-year, and it set Q1 2026 guidance of $0.70–$0.76 EPS.
• About 79.5% of the stock is owned by institutions, analysts carry a consensus "Moderate Buy" rating with an average price target of $96.14, and insiders sold roughly 79,144 shares in the past 90 days.

Blair William & Co. IL decreased its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 4.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 372,353 shares of the medical research company's stock after selling 17,780 shares during the period. Blair William & Co. IL owned 0.06% of Edwards Lifesciences worth $28,958,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. True Wealth Design LLC raised its holdings in Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock worth $28,000 after purchasing an additional 259 shares during the last quarter. Hantz Financial Services Inc. boosted its stake in shares of Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company's stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Rakuten Securities Inc. boosted its stake in shares of Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $30,000. Finally, Strengthening Families & Communities LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $34,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 2.6%

NYSE:EW opened at $81.71 on Friday. The stock has a 50-day simple moving average of $82.56 and a 200 day simple moving average of $81.47. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a market cap of $47.46 billion, a PE ratio of 44.65, a PEG ratio of 2.13 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the previous year, the firm posted $0.59 EPS. The company's revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of several analyst reports. Piper Sandler restated an "overweight" rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Friday, December 5th. Barclays reiterated an "overweight" rating and set a $104.00 target price (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Canaccord Genuity Group set a $87.00 price target on Edwards Lifesciences and gave the company a "hold" rating in a research note on Wednesday, December 17th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $96.14.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the firm's stock in a transaction on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 79,144 shares of company stock valued at $6,685,688 over the last 90 days. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.